Treatment with a new benzimidazole derivative bearing a pyrrolidine side chain overcomes sorafenib resistance in hepatocellular carcinoma

Hepatocellular carcinoma (HCC) is a major cause of cancer-related death worldwide. Currently, sorafenib is the standard first-line drug for patients with advanced HCC. However, long-term exposure to sorafenib often results in reduced sensitivity of tumour cells to the drug, leading to acquired resis...

Descripción completa

Detalles Bibliográficos
Autores principales: Suk, Fat-Moon, Liu, Chao-Lien, Hsu, Ming-Hua, Chuang, Yu-Ting, Wang, Jack P., Liao, Yi-Jen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6872581/
https://www.ncbi.nlm.nih.gov/pubmed/31754201
http://dx.doi.org/10.1038/s41598-019-53863-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6872581/
https://www.ncbi.nlm.nih.gov/pubmed/31754201
http://dx.doi.org/10.1038/s41598-019-53863-2

Ejemplares similares